PRINCETON, N.J. – March 1, 2023 – Certara, Inc. (Nasdaq: CERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023. Mr. Schemick will transition into a newly created position as Senior Vice President, Corporate Operations and Integration, and he will be focused on supporting John’s transition, and … Continued
PRINCETON, N.J.— February 27, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global Healthcare Conference. Company management will present at 11:15AM ET on Wednesday, March 15th, 2023. A live webcast of the event will be available on Certara’s investor relations website at … Continued
PRINCETON, N.J.— February 1, 2023– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. … Continued
Certara improves software capabilities by expanding into deep learning and data fabric PRINCETON, N.J.— January 4, 2023 — Certara, Inc. (Nasdaq: CERT), today announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The acquisition will elevate Certara’s software by bringing state-of-the-art artificial intelligence (AI) capabilities to its end-to-end platform. “We are pleased to … Continued
Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity PRINCETON, N.J.— December 8, 2022 — Certara, Inc. (Nasdaq: CERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare companies, closed its previously announced $449 million new investment in Certara. … Continued
Biosimulation software and services fuel third quarter growth PRINCETON, N.J.— November 7, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2022 and reiterated its full year guidance. Third Quarter Highlights: Revenue was $84.7 million, compared to $73.9 million in the third … Continued
Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares PRINCETON, N.J.— November 7, 2022 — Certara, Inc. (Nasdaq: CERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare … Continued
PRINCETON, N.J.— November 2, 2022 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Jeffries London Healthcare ConferenceDate and Time: Tuesday, November 15 at 4:25PM GMT Stephens Annual Investment ConferenceDate and Time: Thursday, November 17 at 9:00AM CT Live webcasts for each … Continued
The PMDA enters 9th consecutive year of using Certara’s software PRINCETON, N.J., October 19, 2022 — Certara, Inc., (Nasdaq: CERT) a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ Simulator, Phoenix™ biosimulation software, and Pinnacle 21™ Enterprise software. “The adoption of biosimulation … Continued
PRINCETON, N.J.— October 13, 2022– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in … Continued
